Effect of Active Drain Line Clearance on Catheter-Associated Bacteriuria (CAB)
Primary Purpose
Critical Illness, Burns, Surgery
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Standard of Care
DLC Group
DLCS Group
Sponsored by
About this trial
This is an interventional prevention trial for Critical Illness focused on measuring urinary catheter
Eligibility Criteria
Inclusion Criteria:
- Adult (age ≥ 18)
- Patient or Legally Authorized Representative (LAR) possess the capacity to provide informed consent
- Indication for a urinary bladder catheter (or one currently in place)
- Expected urinary catheter requirement ≥ 72 hours
- No current urinary tract infection
- No current indication for prophylactic antibiotics. If a surgical patient, receive perioperative antibiotics for no greater than 24 hours
Exclusion Criteria:
- Inability to receive a urinary bladder catheter
- Chronic suprapubic catheter in place
- Expected survival < 72 hours
- Receipt of systemic antibiotics within 48 hours of enrollment, other than prophylactic antibiotics given at the time of surgery
- Surgery of the genitourinary tract in the past 6 months prior to admission
- Deemed unfit for the protocol by the investigator for any reason
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Experimental
Experimental
Arm Label
Standard of Care
Drain Line Clearance (DLC) Group
Drain Line Clearance and Silver (DLCS) Group
Arm Description
Patients will receive Standard of Care, commercially available catheter utilized by hospital system.
Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and plain silicone catheter.
Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and silver-doped silicone catheter.
Outcomes
Primary Outcome Measures
Difference in percentage of catheter-associated bacteriuria
To study the difference in rate of catheter-associated bacteriuria between SOC catheters and Accuryn silicone or Accuryn silver-doped catheters with active drain line clearance.
Secondary Outcome Measures
Percentage of asymptomatic (ASB) and symptomatic (CAUTI) bacteriuria
To study the incidence and progression of asymptomatic bacteriuria and CAUTI in patients with prolonged foley catheters for greater than 72 hours.
Time to Bacteriuria (ASB and CAUTI)
To study the progression of asymptomatic bacteriuria and CAUTI in patients with prolonged foley catheters for greater than 72 hours.
Urine Culture Comparisons
To study the correlation between patient urine cultures and cultures taken from the Foley (Foley tip, urine sampled from collection bag).
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03816384
Brief Title
Effect of Active Drain Line Clearance on Catheter-Associated Bacteriuria
Acronym
CAB
Official Title
Effect of Active Drain Line Clearance With or Without Silver on Catheter-Associated Bacteriuria (The CAB Study)
Study Type
Interventional
2. Study Status
Record Verification Date
January 2020
Overall Recruitment Status
Withdrawn
Why Stopped
Declined to pursue Study due to anticipated low enrollment numbers
Study Start Date
January 31, 2020 (Anticipated)
Primary Completion Date
January 31, 2020 (Anticipated)
Study Completion Date
January 31, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Potrero Medical
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Catheter-associated urinary tract infections (CAUTI) are the most common nosocomial infections in critically ill patients and are responsible for high morbidity rates, increased hospital stays and associated costs.
The purpose of this study is to evaluate whether active drain line clearance by the Accuryn Monitoring System reduces the incidence of CAUTI in hospitalized patients requiring catheters.
Detailed Description
Urinary tract infection (UTI) is the most common healthcare associated infection (HAI) acquired in hospitals and is estimated to account for approximately 13% of hospital infections in the United States, of which 75% are associated with indwelling urinary catheters. It is estimated that between 12-16% adult inpatients will receive an indwelling urinary catheter during their hospital stay. The rate of catheter-associated UTI (CAUTI) are highest in burn ICUs, followed by inpatient medical wards and neurosurgical ICUs.
The purpose of this study is to evaluate whether active drain line clearance by the Accuryn Monitoring System reduces the incidence of bacteriuria and/or CAUTI in patients requiring catheters for more than 72 hours. This study will also evaluate the efficacy in reducing bacteriuria of the Accuryn silver fabricated silicone catheters.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Illness, Burns, Surgery, Urinary Tract Infections, Bacteriuria
Keywords
urinary catheter
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Multi-center, Randomized-Controlled-Trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Standard of Care
Arm Type
Active Comparator
Arm Description
Patients will receive Standard of Care, commercially available catheter utilized by hospital system.
Arm Title
Drain Line Clearance (DLC) Group
Arm Type
Experimental
Arm Description
Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and plain silicone catheter.
Arm Title
Drain Line Clearance and Silver (DLCS) Group
Arm Type
Experimental
Arm Description
Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and silver-doped silicone catheter.
Intervention Type
Device
Intervention Name(s)
Standard of Care
Intervention Description
Standard of care urinary drainage system.
Intervention Type
Device
Intervention Name(s)
DLC Group
Intervention Description
Urinary drainage system with active drain line clearance and plain silicone catheter.
Intervention Type
Device
Intervention Name(s)
DLCS Group
Intervention Description
Urinary drainage system with active drain line clearance and silver-doped silicone catheter.
Primary Outcome Measure Information:
Title
Difference in percentage of catheter-associated bacteriuria
Description
To study the difference in rate of catheter-associated bacteriuria between SOC catheters and Accuryn silicone or Accuryn silver-doped catheters with active drain line clearance.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Percentage of asymptomatic (ASB) and symptomatic (CAUTI) bacteriuria
Description
To study the incidence and progression of asymptomatic bacteriuria and CAUTI in patients with prolonged foley catheters for greater than 72 hours.
Time Frame
30 days
Title
Time to Bacteriuria (ASB and CAUTI)
Description
To study the progression of asymptomatic bacteriuria and CAUTI in patients with prolonged foley catheters for greater than 72 hours.
Time Frame
30 days
Title
Urine Culture Comparisons
Description
To study the correlation between patient urine cultures and cultures taken from the Foley (Foley tip, urine sampled from collection bag).
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult (age ≥ 18)
Patient or Legally Authorized Representative (LAR) possess the capacity to provide informed consent
Indication for a urinary bladder catheter (or one currently in place)
Expected urinary catheter requirement ≥ 72 hours
No current urinary tract infection
No current indication for prophylactic antibiotics. If a surgical patient, receive perioperative antibiotics for no greater than 24 hours
Exclusion Criteria:
Inability to receive a urinary bladder catheter
Chronic suprapubic catheter in place
Expected survival < 72 hours
Receipt of systemic antibiotics within 48 hours of enrollment, other than prophylactic antibiotics given at the time of surgery
Surgery of the genitourinary tract in the past 6 months prior to admission
Deemed unfit for the protocol by the investigator for any reason
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin Foster, MD
Organizational Affiliation
Maricopa Integrated Health System (MIHS)
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of Active Drain Line Clearance on Catheter-Associated Bacteriuria
We'll reach out to this number within 24 hrs